CARSON BENJAMIN SR 4

What Happened

• Benjamin Carson Sr, a director of Galectin Therapeutics, was granted a derivative award of 60,000 shares (reported as a grant/acquisition) on January 16, 2026. The Form 4 reports a $0.00 per-share amount and $0 total value for the grant. The award is a equity-based derivative instrument (options/awards), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-16 (reported on Form 4 filed 2026-01-21)
• Type: Grant / Award of derivative securities (transaction code A)
• Amount: 60,000 shares (derivative)
• Reported price: $0.00 per share (Form 4 shows $0 total)
• Vesting: 100% vests on December 31, 2026 (per footnote: issued under the 2019 Omnibus Equity Incentive Plan)
• Shares owned after transaction: Not specified in the provided filing
• Timeliness: Form 4 was filed Jan 21, 2026 — outside the typical 2-business-day Form 4 reporting window for Jan 16 transactions (filed 5 calendar days later); late filings can reduce transparency for investors

Context

• This was a grant of derivative awards under the company’s 2019 Omnibus Equity Incentive Plan. The Form 4 does not indicate an exercise or sale of shares, nor an immediate cashless transaction. Grants like this are typically compensation/retention awards; they are not direct buy or sell signals.